Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in ...

(EBC) patients receiving Kisqali in 1-year post-treatment analysis 1 Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients 1 ...